Key result
Tested sera maintain protective neutralizing antibody levels across diverse measles virus genotypes.
Why the study?
The genetic and antigenic diversity of vaccine-type and wild-type measles viruses needed to be determined using different antisera in a neutralization assay.
Protective antibody levels were maintained against different genotypes of wild-type measles virus, suggesting that genetic variation does not compromise the efficacy of the current vaccine.
Answers are grounded in this paper and cite their sources.
Neutralization occurs across measles antigenic variants; leaves open whether current vaccines retain full efficacy against evolving wild-type strains.
The aim of this study was to determine the genetic and antigenic diversity of vaccine-type and wild-type measles viruses by using different antisera in a neutralization assay. Virus strains included genotype A, D3 and D6 clades, and five different groups of antibodies were used. Wild-type measles viruses isolated in Turkey have been classified as D6 and the others isolated in Japan as D3. Antisera used in the assay were against genotype A, D3 and D6. Regardless of the antigenic diversity, protective antibody level (> or = 1/16) was determined against different genotypes of measles virus.
No takes yet. Share an insight, caveat, or question.
Korukluoğlu et al. (2006) studied Measles (n=13). Measles virus genotypes (A, D3, D6) vs. Vaccine strain (Edmonston) was evaluated on Neutralizing antibody titer. Regardless of antigenic diversity, protective neutralizing antibody levels (≥1/16) were maintained against different genotypes of measles virus (A, D3, and D6) across all tested sera.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: